Table 6.
Follow-up characteristics of iTTP patients included in the cohort study.
| All iTTP Patients (n = 153) | TT (n = 18) |
CT (n = 66) |
CC (n = 69) |
|
|---|---|---|---|---|
| Median follow-up time, years (95% CI) * | 4.9 (3.7 to 6.1) |
3.6 (0.0 to 7.5) |
5.8 (5.0 to 6.7) |
4.0 (2.9 to 5.1) |
| Relapse n (%) | 44 (29) | 3 (17) | 13 (20) | 28 (41) |
| Death n (%) | 3 (2) | 2 (12) | 0 | 1 (1) |
| Cancer n (%) | 3 (2) | 0 | 2 (3) | 1 (1) |
| Censored alive at the end of study, n (%) | 92 (60) | 12 (67) | 48 (73) | 32 (46) |
| Censored alive lost to follow-up, n (%) | 11 (7) | 2 (11) | 3 (5) | 6 (9) |
CI, confidence interval; iTTP, immune-mediated thrombotic thrombocytopenic purpura. * Estimated by the inverse Kaplan–Meier method.